InvestorsHub Logo
Followers 2
Posts 352
Boards Moderated 0
Alias Born 04/02/2013

Re: Gpheart2013 post# 2208

Wednesday, 10/05/2016 2:47:44 PM

Wednesday, October 05, 2016 2:47:44 PM

Post# of 6401
Details of the Ib/IIa CML study: enrollment will begin November 2016. The Ib portion will be a safety study using increasing doses of BP1001 along with dasatinib to determine the optimal dose of BP1001. The IIa study will use a fixed dose of BP 1001 (as determined from the Ib study) to test the efficacy of the combination BP 1001/dasatinib. They anticipate 46 patients over three years.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BPTH News